Vagus Nerve Stimulation Shows Promise in Treating Multidrug-Refractory Rheumatoid Arthritis

Researchers have found that vagus nerve stimulation can modulate systemic inflammation and may represent a novel non-pharmacologic treatment modality for autoimmune diseases like rheumatoid arthritis. The study, conducted over a 36-month period, involved 14 patients with active RA who had previously failed an average of 4.8 different drugs. The results showed significant improvements in clinical disease activity, with 64% of patients achieving a clinical response that met or exceeded the minimal clinically important difference.

Key Takeaways:

• The study involved 14 patients with multidrug-refractory RA who were implanted with a novel neuroimmune modulation device that stimulates the cervical vagus nerve.
• Patients were treated for 12 weeks and then assessed for safety and clinical effectiveness in an open-label 36-month extension study.
• The median change in clinical disease activity index (CDAI) score from day 0 to month 36 was -17.8 (SEM 4.9).
• At month 36, 64% (7/11) of patients achieved a CDAI response that met or exceeded the minimal clinically important difference.
• No device-related infections, cardiac events, surgical revisions, or device explants were reported.
• The study showed that neuroimmune modulation was well tolerated among patients with multidrug-refractory RA, with reductions of clinical disease activity that were maintained through 36 months.

Statistics:

• 50% of patients with drug-refractory RA improved clinically in a 3-month double-blind trial.
• 30-50% of pro-inflammatory cytokines declined with daily stimulation.
• 64% (9/14) of patients had failed a targeted synthetic disease-modifying antirheumatic drug (tsDMARD) before enrolling in the study.
• The average number of failed treatment drugs per patient was 4.8.
• 11 patients completed the 36-month extension study.
• 7 of 11 patients achieved a CDAI response that met or exceeded the minimal clinically important difference.

Sources:

• Neuroimmune Modulation for Drug-Refractory Rheumatoid Arthritis: Long-Term Safety and Efficacy in Patients Enrolled in a Pilot Vagus Nerve Stimulation Study. Rheumatology and Therapy, 2025.
• Investigators at Department of Rheumatology Have Reported New Data on Rheumatoid Arthritis (Neuroimmune Modulation for Drug-Refractory Rheumatoid Arthritis: Long-Term Safety and Efficacy in Patients Enrolled in a Pilot Vagus Nerve Stimulation ...). Medical Devices & Surgical Technology Week. October 26, 2025; p 723.